explore -WSS

explore

author：knowledge 2025-09-27 12:47:43 - browse：8

Home health and hospice chain Amedisys has chosen a new corporate owner.

Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Novo acquires Inversago for up to $1 billion

explore

WSS

Where are patients getting their prescriptions for GLP

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Novo Nordisk to expand supply of Wegovy for U.S. patients

Pharma budget tightening trickles down to Doximity

Vertigo drug brings hope for rare neuron disorder, Niemann

Novo Nordisk to expand supply of Wegovy for U.S. patients

leisure time

explore

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

FDA drug safety: Singulair case shows systemic surveillance flaws

Medical records are filled with copy

Novo acquires Inversago for up to $1 billion

Dobbs anniversary: the lost opportunity of abortion as health care

General Catalyst, Summa Health deal will turn on physician buy

Peter Hotez and the public health issue of online harassment

FDA drug safety: Singulair case shows systemic surveillance flaws

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

A $475,000 price tag for a new cancer drug: crazy or meh?

leisure time

Vertex non

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Newly revealed memo details efforts to keep Trump in power following election loss

Kim Kardashian sparks debate on benefits of full

Timeline: Special counsel's investigation into Trump's handling of classified documents

Time to name cancers by genetics, not organ of origin, expert says

knowledge

explore

explore

leisure time